Diabetes Clinical Trials in Phoenix

Showing 61-80 of 537 trials

Outcomes of Physiologic Insulin Resensitization (PIR) in Patients With Chronic Kidney Disease and Type 2 Diabetes Mellitus

NCT07187479

The purpose of this research is to evaluate outcomes of physiologic insulin re-sensitization (PIR) in patients with Chronic Kidney Disease (CKD) and Type 2 Diabetes Mellitus (T2DM).

Chronic Kidney Disease (Stages 4 and 5)Kidney DiseaseType 2 Diabetes

Well Cell Global120 participantsStarted Oct 2025

Phoenix, Arizona, United States

COMPLETEDPhase 3< 1 mile

A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor

NCT06109311

The main purpose of this study is to determine the safety and efficacy of orforglipron. Participants will have Type 2 Diabetes (T2D) and have inadequate glycemic control with insulin glargine with or without metformin and/or SGLT-2 (sodium-glucose cotransporter-2) inhibitor. The study will last about 46 weeks and may include up to 20 visits.

Type 2 Diabetes

Eli Lilly and Company546 participantsStarted Nov 2023

Chandler, Arizona, United States • Phoenix, Arizona, United States • Bryant, Arkansas, United States +67 more locations

Outcomes of Physiologic Insulin Resensitization (PIR) in Patients With Chronic Kidney Disease and Type 2 Diabetes Mellitus

A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor

Diabetes Trials in Other Cities

A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin

A Study of LY3549492 in Adults With Obesity or Overweight With Type 2 Diabetes

The Diabetes Prevention Program Outcomes Study AD/ADRD Project

A Study to Learn How Well the Study Treatment Finerenone Works and How Safe it is in People With Long-term Decrease in the Kidneys' Ability to Work Properly (Chronic Kidney Disease) Together With Type 1 Diabetes

DFC 004 Biomarkers for Active Diabetic Foot Ulcers

Gla-300 and IDeg-100 in Insulin-Naïve People With Type 2 Diabetes Mellitus and Renal Impairment

A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin

Study Of Drinks With Artificial Sweeteners in People With Type 2 Diabetes

Phase 2b Trial Comparing HDV-Insulin Lispro to Insulin Lispro in Adults With Type 1 Diabetes Receiving Insulin Degludec

Investigational Extended Wear Insulin Infusion Set in People With Type 1 Diabetes

Assess the Efficacy and Safety of Repeat Intravitreal Injections of Foselutoclax (UBX1325) in Patients With DME (ASPIRE)

Denosumab for Type 1 Diabetes

OP5-005 Using Omnipod 5 in Adults With Type 2

Omnipod 5 System Compared to Pump Therapy

A Study to Evaluate ENERGI-F703 GEL in Diabetic Foot Ulcer

XW014 in Healthy Subjects and Patients With Type 2 Diabetes Mellitus (T2DM)

HLA Demographics Study in Adults With Type 1 Diabetes

An Efficacy, Safety, and Tolerability Study of VX-880 in Participants With Type 1 Diabetes With a Kidney Transplant

Other Conditions in Phoenix